Ref. Design and location Comorbidities, % Severity, % Days from symptoms onset Treatment regimen (mg) Number of patients Main results
Gautret et al.[8]
Multicenter, open-label, non-randomized CT, France
HBP: NR Diabetes: NR Obesity: NR Asymptomatic: 16.7 URTI symptoms: 61.1
4
500 day 1, 250 OD days 2-5
PCR negative day 6 (P=0.001)
HCQ: 20 57.1 %
HCQ + AZT: 6 100 %
SOC: 16 12.5 %
Gautret et al.[72]
Single center, retrospective, observational study, France
HBP: 16 Diabetes: 11 Obesity: 5 Asymptomatic: 5.0 URTI symptoms: 41.2 NEWS low (0-4): 92
5
500 day 1, 250 OD days 2-5
HCQ + AZT: 80
Day 7: 81 % clinical cure 3.8 % transferred to ICU 83 % PCR negative
Million et al.[73]
Single center, retrospective, observational study, France
HBP: 14 Diabetes: 7 Obesity: 6
NEWS low (0-4): 95
6
500 day 1, 250 OD days 2-5
HQC + AZT: 1,061
Day 7: 91.7 % clinical and virological cure 0.9 % transferred to ICU 0.8 % died
Molina et al.[74]
Single center, retrospective, observational study, France
HBP: NR Diabetes: NR Obesity: 18 Cancer: 46
NR
NR
500 day 1, 250 OD days 2-5
HCQ + AZT: 11
Day 5: 9 % died 18.2 % transferred to ICU Day 6: 80 % PCR positive
Mahevas et al.[75]
Multicenter, retrospective, propensity-score matched observational study, France
HBP: 51 Diabetes: 9 Obesity: 26
>50 % extend on CT: 33
7
500 day 1, 250 OD days 2-5
21-day mortality % and HR:
HCQ: 84 HCQ + AZT: 15
HCQ: 11 %, 1.2 (95 % CI 0.4-3.3)
Control: 89 AZT: 26 (29.2 %)
Control: 9 %. Reference
Magagnoli et al.[76]
National retrospective, propensity-score matched observational study, USA
HBP: NR Diabetes: 67.7 BMI: 29.8 Charlson: 2.3 Albumin < 2.8 g/dL: 17.6 Heart rate >100 lpm: 15.5
NR
NR
In-hospital mortality % and aHR:
HCQ: 198 19.2, 1.83 (95 % CI 1.16-2.89)
HCQ + AZT: 214 22.9, 1.31 (95 % CI 0.80-2.15)
No HCQ: 395 AZT: 91 (23.0 %)
9.4 %. Reference
Geleris et al.[77]
Single center, retrospective, propensity-score matched observational study, USA
HBP: 52 Diabetes: 36 Obesity: 41 Median values: Pao2/Fio2: 248 mmHg Oxygen saturation: 94 % Heart rate: 98 bpm Ferritin: 665 ng/ml
NR
500 day 1, 250 OD days 2-5
HCQ: 811 HCQ + AZT: 486 (59.9 %) Time to intubation or death HR: HCQ: 1.04 (95 % CI 0.82-1.32) AZT: 1.03 (95 % CI 0.81-1.31)
No HCQ: 274 AZT: 102 (37.2 %)
Rosenberg et al.[78]
Multicenter, retrospective, observational study, USA
HBP: 57 Diabetes: 7 Obesity: 43 ICU: 12.8 Mechanical ventilation: 9.5
NR
500 OD. Unknown duration
In-hospital mortality aHR:
HCQ + AZT: 735 1.35 (95% CI 0.76-2.40)
HCQ: 271 1.08 (95 % CI 0.63-1.85)
AZT: 211 0.56 (95 % CI 0.26-1.21)
SOC: 221 Reference
Guerin et al.[79]
Retrospective, observational study, France
HBP: 12.8 Diabetes: 3.4 Obesity: 13.6
Outpatients
1 (41 %) Within 15 (57.9)
500 day 1, 250 OD days 2-5
Time to clinical recovery, median (range):
HCQ + AZT: 20 7 (2-40)
AZT: 34 7 (3-48)
SOC: 34 27 (6-48)
Barbosa et al.[80]
Open label, controlled non-randomized trial, Brazil
HBP: 26.5 Diabetes: 13.4 Obesity: 7.7
Outpatients
5.2 ± 3.1
500 OD 5 days
Need for hospitalization
HCQ+AZT: 412 1.9 %
SOC: 224 5.4 %